1,609 results on '"Suzuki, Fumitaka"'
Search Results
152. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
153. Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease
154. Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma
155. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
156. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
157. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
158. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C
159. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology
160. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
161. Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy
162. Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
163. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
164. Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis
165. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
166. Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant
167. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B.
168. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
169. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes
170. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course
171. Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma
172. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C
173. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load
174. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
175. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with chronic hepatitis B: 357
176. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load
177. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma
178. Determinants of Response to Triple Therapy of Telaprevir, Peginterferon, and Ribavirin in Previous Non-Responders Infected With HCV Genotype 1
179. Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL
180. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients
181. Transcatheter Arterial Chemotherapy Using Miriplatin–Lipiodol Suspension with or without Embolization for Unresectable Hepatocellular Carcinoma
182. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively
183. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy
184. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
185. Amino Acid Substitutions in Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by Antiviral Therapy
186. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy
187. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model
188. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
189. Influence of Itpa Polymorphisms on Decreases of Hemoglobin During Treatment With Pegylated Interferon, Ribavirin, And Telaprevir
190. Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
191. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
192. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
193. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
194. Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection
195. Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment
196. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C
197. Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma
198. Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease
199. Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver
200. Splenic Abscess and Tumor Thrombosis Associated with Colon Cancer—A Case Report—
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.